These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30243036)

  • 1. Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder.
    Meshberg-Cohen S; Black AC; DeViva JC; Petrakis IL; Rosen MI
    Addict Behav; 2019 Feb; 89():29-34. PubMed ID: 30243036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observational Evidence for Buprenorphine's Impact on Posttraumatic Stress Symptoms in Veterans With Chronic Pain and Opioid Use Disorder.
    Seal KH; Maguen S; Bertenthal D; Batki SL; Striebel J; Stein MB; Madden E; Neylan TC
    J Clin Psychiatry; 2016 Sep; 77(9):1182-1188. PubMed ID: 27035058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Opioid Use Disorder Diagnoses and Medication Treatment Among Veterans With Posttraumatic Stress Disorder.
    Shiner B; Leonard Westgate C; Bernardy NC; Schnurr PP; Watts BV
    J Dual Diagn; 2017; 13(3):201-212. PubMed ID: 28481727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A; Quinones L; Rosenheck R
    Drug Alcohol Depend; 2016 Mar; 160():82-9. PubMed ID: 26804898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobile, Community-Based Buprenorphine Treatment for Veterans Experiencing Homelessness With Opioid Use Disorder: A Pilot, Feasibility Study.
    Iheanacho T; Payne K; Tsai J
    Am J Addict; 2020 Nov; 29(6):485-491. PubMed ID: 32367557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posttraumatic stress disorder in individuals seeking treatment for opioid use disorder in Vermont.
    Peck KR; Moxley-Kelly N; Badger GJ; Sigmon SC
    Prev Med; 2021 Nov; 152(Pt 2):106817. PubMed ID: 34599919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A; Petrakis I; Rosenheck R
    Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful engagement in buprenorphine treatment among hospitalized patients with opioid use disorder and trauma.
    Bhatraju EP; Ludwig-Barron N; Takagi-Stewart J; Sandhu HK; Klein JW; Tsui JI
    Drug Alcohol Depend; 2020 Oct; 215():108253. PubMed ID: 32890919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
    Berger R; Pulido C; Lacro J; Groban S; Robinson S
    J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.
    Finlay AK; Harris AH; Rosenthal J; Blue-Howells J; Clark S; McGuire J; Timko C; Frayne SM; Smelson D; Oliva E; Binswanger I
    Drug Alcohol Depend; 2016 Mar; 160():222-6. PubMed ID: 26832998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttraumatic stress disorder in opioid agonist therapy: A review.
    Ecker AH; Hundt N
    Psychol Trauma; 2018 Nov; 10(6):636-642. PubMed ID: 28758767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group-based treatment of opioid use disorder with buprenorphine: A systematic review.
    Sokol R; LaVertu AE; Morrill D; Albanese C; Schuman-Olivier Z
    J Subst Abuse Treat; 2018 Jan; 84():78-87. PubMed ID: 29195596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
    Ching JH; Owens DK; Trafton JA; Goldhaber-Fiebert JD; Salomon JA
    Addiction; 2021 Dec; 116(12):3494-3503. PubMed ID: 33999485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.
    Kelly MM; Reilly E; Quiñones T; Desai N; Rosenheck R
    Drug Alcohol Depend; 2018 Feb; 183():111-117. PubMed ID: 29245103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective Review of a Novel Approach to Buprenorphine Induction in the Emergency Department.
    Dunkley CA; Carpenter JE; Murray BP; Sizemore E; Wheatley M; Morgan BW; Moran TP; Steck A
    J Emerg Med; 2019 Aug; 57(2):181-186. PubMed ID: 31060846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do people with opioid use disorder and posttraumatic stress disorder benefit from dding Individual opioid Drug Counseling to buprenorphine?
    McHugh RK; Hilton BT; Chase AM; Griffin ML; Weiss RD
    Drug Alcohol Depend; 2021 Nov; 228():109084. PubMed ID: 34607194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.